FreeTheAI

Dermata Therapeutics Shares Rise After Positive Clinical Trial Results

BullishMedium impact
DRMA$0.9100 37.19%

Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares moved higher on Thursday after the biotech company reported positive trial data for its recently released skincare product. Topline results from a cosmetic clinical study showed noticeable improvements across key metrics for participants using the company's Tome Foundational Treatment.

The four-week study evaluated 31 participants who applied the skincare product once per week. Self-evaluations following the trial revealed that 93% of participants considered the results comparable to professional in-office procedures, while 90% reported clearer results than competing treatments. No adverse events related to the application were recorded during the trial.

The study outcomes provide support for Dermata Therapeutics' commercial push into the skincare market following the product's launch in August. Investors will be monitoring whether the positive clinical feedback translates into sales growth for the online-available treatment as adoption expands.

Key points

  • Dermata Therapeutics reported positive topline results from a four-week cosmetic clinical study of its Tome Foundational Treatment.
  • In the 31-participant study, 93% agreed the weekly skincare treatment was comparable to a professional in-office procedure.
  • No treatment-related adverse events were reported during the study.
  • The product launched commercially in August and is currently available for purchase online.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Dermata Therapeutics stock rise on Thursday?

Dermata Therapeutics stock rose after the company announced positive clinical trial results for its Tome Foundational Treatment skincare product.

What were the key findings of the Tome Foundational Treatment study?

The study of 31 participants found that 93% rated the treatment comparable to a professional procedure and 90% saw better results than other products, with no reported adverse events.

Is Tome Foundational Treatment available to consumers?

Yes, Dermata Therapeutics commercially launched Tome Foundational Treatment in August, and the product is available for purchase online.